<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02890602</url>
  </required_header>
  <id_info>
    <org_study_id>EPOMA</org_study_id>
    <nct_id>NCT02890602</nct_id>
  </id_info>
  <brief_title>Erythropoietin for Management of Anemia Caused by Chemotherapy</brief_title>
  <official_title>A Phase Ⅱ Study of Erythropoietin for Management of Anemia Caused by Chemotherapy in Patients With Diffuse Large B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kosin University Gospel Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kosin University Gospel Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase Ⅱ study of erythropoietin for management of anemia caused by chemotherapy in&#xD;
      patients with Diffuse Large B-cell Lymphoma. The investigators want to investigate&#xD;
      hematopoietic response of darbepoietin alfa and the quality of life assessment of&#xD;
      increasement of hemoglobin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Darbepoietin alfa may cause the body to make more red blood cells. They are used to treat&#xD;
      anemia caused by chemotherapy in patients with malignant lymphoma. Darbepoietin will be&#xD;
      applied to R-CHOP(Rituximab, Cyclophosphamide, Adriamycin, Vincristine, Prednisolone)&#xD;
      chemotherapy every 21days ± 2days with fixed 360㎍. It will be applied to chemotherapy until&#xD;
      increment of hemoglobin 12.0g/dL. If the hemoglobin level exceeds 12.0g/dL, administration of&#xD;
      darbepoietin will be temporarily stopped.&#xD;
&#xD;
      And, the questionnaire of the quality of life will be conducted at the baseline, after 2th&#xD;
      darbepoietin alfa administration, at study completion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1, 2012</start_date>
  <completion_date type="Actual">December 7, 2017</completion_date>
  <primary_completion_date type="Actual">November 28, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hematopoietic response</measure>
    <time_frame>hemoglobin level of day 21 after Darbepoietin alfa administration</time_frame>
    <description>Hemoglobin level after Darbepoietin alfa administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by Functional Assessment of Cancer Therapy Scales for anemia</measure>
    <time_frame>at baseline, Day 21 after 2th darbepoietin alfa administration, Day 21 after last darbepoietin alfa administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events as measured by CTCAE v3.0</measure>
    <time_frame>From the date of first drug administration to the date of the 30th days of last drug administration.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients requiring red blood cell transfusions</measure>
    <time_frame>From the date of first darbepoietin alfa administration to day 21 after last darbepoietin alfa administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time to response of hemoglobin</measure>
    <time_frame>From the date of first darbepoietin alfa administration to day 21 after last darbepoietin alfa administration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Diffuse Large B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Darbepoietin alfa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hemoglobin level will be checked at every cycle's day 0 or 1(1cycle is 21days) after starting Darbepoietin alfa. It will be applied to chemotherapy until increment of hemoglobin 12.0 g/dL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darbepoetin alfa</intervention_name>
    <description>Darbepoietin alfa will be administered subcutaneously at a fixed dose of 360㎍. If it is impossible, administration by intravenous infusion is okay.</description>
    <arm_group_label>Darbepoietin alfa</arm_group_label>
    <other_name>Nesp</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-CHOP</intervention_name>
    <description>R-CHOP regimen is a practical procedure in patients with Diffuse Large B-cell Lymphoma. Darbepoietin alfa will be administered to these patients.</description>
    <arm_group_label>Darbepoietin alfa</arm_group_label>
    <other_name>Rituximab, Cyclophosphamide, Adriamycin, Vincristine, Prednisolone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed diffuse large B cell lymphoma treated with R-CHOP(Rituximab,&#xD;
             Cyclophosphamide, Adriamycin, Vincristine, Prednisolone) chemotherapy&#xD;
&#xD;
          2. hemoglobin &lt; 10.0 g/dL are shown at least 3 cycles after starting R-CHOP(Rituximab,&#xD;
             Cyclophosphamide, Adriamycin, Vincristine, Prednisolone)&#xD;
&#xD;
          3. Currently receiving or planning to receive at least 4 times of darbepoetin&#xD;
&#xD;
          4. Age &gt; 18 years&#xD;
&#xD;
          5. ECOG(Eastern Cooperative Oncology Group) performance status 0-2&#xD;
&#xD;
          6. Bilirubin &lt; 2 times upper limit of normal&#xD;
&#xD;
          7. ALT(alanine aminotransferase) or AST(aspartate aminotransferase) &lt; 5 times upper limit&#xD;
             of normal&#xD;
&#xD;
          8. Creatinine &lt; 2 times upper limit of normal&#xD;
&#xD;
          9. HIV negative&#xD;
&#xD;
         10. Ferritin &gt; 20 mcg/L (i.e., not obviously iron deficient)&#xD;
&#xD;
         11. Can read Quality of life as measured by Functional Assessment of Cancer Therapy Scales&#xD;
             for Anemia&#xD;
&#xD;
         12. Agree with informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received radiation therapy at least 4 weeks before starting chemotherapy&#xD;
&#xD;
          2. serious pre-existing medical condition (e.g., cardiac failure [New York Heart&#xD;
             Association Class III or IV, or left ventricular ejection fraction &lt;50%], active&#xD;
             peptic ulceration, uncontrolled diabetes mellitus, or acute diffuse infiltrative&#xD;
             pulmonary disease)&#xD;
&#xD;
          3. uncontrolled hypertension, defined as systolic blood pressure (BP) ≥ 180 mm Hg and/or&#xD;
             diastolic BP ≥ 100 mm Hg, despite medical therapy&#xD;
&#xD;
          4. arrhythmia NCI CTCAE grade ≥ 2&#xD;
&#xD;
          5. History of previously treated seizures allowed provided the patient has been&#xD;
             seizure-free for a minimum of 3 months&#xD;
&#xD;
          6. active systemic infection requiring treatment, a known diagnosis of human HIV, or&#xD;
             active hepatitis B (hepatitis B carriers were permitted)Malignancy was treated&#xD;
             surgically or with local radiation therapy with curative intent and the patient has&#xD;
             been disease free for &gt; 3 years&#xD;
&#xD;
          7. known hypersensitivity to darbepoetin alfa&#xD;
&#xD;
          8. pregnant or nursing and Negative pregnancy test&#xD;
&#xD;
          9. previous diagnosis of another malignancy with radiographic or biochemical evidence of&#xD;
             residual disease (except completely resected basal cell carcinoma, squamous cell&#xD;
             carcinoma of the skin, or an in-situ malignancy)&#xD;
&#xD;
         10. combined iron deficiency anemia&#xD;
&#xD;
         11. received erythropoietin at least one months before starting darbepoetin&#xD;
&#xD;
         12. considered autologous stem cell transplantation before finish 6 cycles of chemotherapy&#xD;
&#xD;
         13. untreated primary or metastatic CNS(central nervous system) malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 18, 2016</study_first_submitted>
  <study_first_submitted_qc>August 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2016</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kosin University Gospel Hospital</investigator_affiliation>
    <investigator_full_name>Ho Sup Lee</investigator_full_name>
    <investigator_title>MD, PhD. associate professor, Division of hematology-Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

